News | February 21, 2022
SEBI approves IPO plans of PharmEasy and Wellness Forever Medicare
The companies plan to use the proceeds to retire debt and expand operations
The companies plan to use the proceeds to retire debt and expand operations
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia
Resolv ER may remedy leading causes of blindness in adults
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
Apexxnar is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible for the majority of invasive disease and pneumococcal pneumonia
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
Subscribe To Our Newsletter & Stay Updated
